Business Context and Reporting Period
This Form 8-K was filed by Cerulean Pharma Inc. on March 20, 2015. The report discloses a significant change in executive leadership and board composition. Note: The request metadata references "Dare Bioscience, Inc.," but the filing text explicitly identifies the registrant as Cerulean Pharma Inc.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes
- Executive Appointment: Christopher D.T. Guiffre was appointed President and Chief Executive Officer, effective immediately.
- Board Expansion: The Board of Directors increased its size from nine to ten members, with Mr. Guiffre appointed as a Class I director.
- Leadership Structure: Paul A. Friedman continues to serve as Executive Chairman.
Compensation, Outlook, and Risks
Compensation Arrangements:
- Base Salary: Increased to $435,000 annually.
- Bonus: Annual target bonus opportunity set at 50% of base salary.
- Equity Grant: Stock option to purchase 407,520 shares, vesting monthly over four years (1/48th per month).
- Severance:
- Standard termination without cause: 12 months of base salary.
- Termination within one year of a change of control: 18 months of base salary plus 1.5 times the higher of target or last paid bonus, plus full acceleration of unvested equity (excluding performance-based awards).
Outlook and Risks: The filing does not provide specific business outlook, risk factors, or contingencies beyond the standard disclosure of the new employment agreement terms. The amended employment agreement is intended to be filed in the next quarterly report on Form 10-Q.
Investor Verification Checklist
- Verify the exact terms of the amended employment agreement once filed in the next Form 10-Q.
- Confirm the exercise price of the 407,520 stock options granted to Mr. Guiffre based on the closing stock price on the grant date.
- Review the press release (Exhibit 99.1) for additional strategic context regarding the leadership transition.
- Monitor future filings for any financial impact related to the new executive compensation structure.